Allergic Rhinitis

Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.

Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.

Desloratadine (Sch34117) is an orally active and selective H1 receptor antagonist (K_i=0.9 nM) with anti-inflammatory and anti-allergic activities. Desloratadine inhibits the release of histamine and LTC4 from human basophils and targets the regulatory signals of IL-4 and IL-13 production in basophils. Desloratadine significantly alleviates SAR symptoms in patients with concurrent asthma and can be used in the study of seasonal allergic rhinitis and chronic idiopathic urticaria.

Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.

Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).

Bradykinin (1-5) is a metabolite of Bradykinin (HY-P0206) and a PAR inhibitor that inhibits thrombin-induced platelet aggregation by preventing protease-activated receptor (Protease Activated Receptor) cleavage and inhibiting Thrombin (MW 37kDa) (HY-114164). Bradykinin (1-5) is used in research on thrombosis, carrageenan-induced pleurisy, nasal allergy, and hereditary angioedema.

Carbinoxamine maleate salt is a blood-brain barrier-permeable histamine H1 receptor antagonist. Carbinoxamine maleate salt blocks the action of histamine on H1 receptors, reducing symptoms such as sneezing, rhinitis, rhinorrhea, erythema, pruritus and urticaria. Carbinoxamine maleate salt inhibits influenza virus entry into cells via endocytosis, targets the early stage of the viral life cycle, and simultaneously reduces viral replication levels in the lungs, alleviating pathological damage and inflammatory responses in lung tissues. Carbinoxamine maleate salt can be used in research on allergic rhinitis, influenza, etc.

trans-Tranilast (trans-MK-341) is an isomer of Tranilast (HY-B0195), and an anti-allergy agent used in studies of bronchial asthma, allergic rhinitis, and atopic dermatitis.

Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia.

Azatadine dimaleate (Azatadine maleate) is an orally active histamine H₁ receptor inhibitor, cetylcholine receptor inhibitor, and serotonin receptor inhibitor. Azatadine dimaleate induces sedation and exhibits topical anesthetic properties. Azatadine dimaleate can be used for the research of allergic rhinitis.

11-Dehydro-thromboxane B2 is a stable terminal metabolite of thromboxane A2 and an agonist of the CRTH2 receptor. 11-Dehydro-TXB2 activates human eosinophils, basophils, and CRTH2-transfected BaF/3 cells through a pertussis toxin-insensitive G protein-PLC pathway, inducing intracellular calcium mobilization, morphological changes, and chemotaxis, but does not affect platelet aggregation. 11-Dehydro-thromboxane B2 is involved in thrombosis and promotes eosinophil recruitment to the lungs in allergic inflammation, and its urinary levels are used to assess the inhibitory effect of Aspirin (HY-14654) on thromboxane production. 11-Dehydro-TXB2 serves as a biomarker for research related to asthma, atopic rhinitis, nephropathy, and coronary artery disease.

TFC-007 is a selective and orally effective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, with an IC₅₀ of 71 nM for H-PGDS. TFC-007 shows weak effects on L-PGDS and various arachidonic acid-related enzymes and receptors. TFC-007 inhibits PGD2 production in KU812 cells without decreasing H-PGDS protein levels. TFC-007 can be used for research on H-PGDS/PGD2 signaling and allergic rhinitis.

(R)-MMP408 is an isomer of MMP408 (HY-12093). MMP408 is an orally active MMP-12 inhibitor (IC₅₀=2.0 nM for hMMP-12) that effectively interferes with the epithelial-mesenchymal transition (EMT) process. MMP408 significantly upregulates the expression of E-cadherin in nasal epithelial cells, while inhibiting mesenchymal markers such as vimentin, α-smooth muscle actin and fibronectin, thereby reversing the EMT phenotype. MMP408 is used in studies of airway remodeling-related diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease (COPD) and asthma.

11-Dehydro-thromboxane B2-d₄ is the d₄-labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a stable terminal metabolite of thromboxane A2 and an agonist of the CRTH2 receptor. 11-Dehydro-TXB2 activates human eosinophils, basophils, and CRTH2-transfected BaF/3 cells through a pertussis toxin-insensitive G protein-PLC pathway, inducing intracellular calcium mobilization, morphological changes, and chemotaxis, but does not affect platelet aggregation. 11-Dehydro-thromboxane B2 is involved in thrombosis and promotes eosinophil recruitment to the lungs in allergic inflammation, and its urinary levels are used to assess the inhibitory effect of Aspirin (HY-14654) on thromboxane production. 11-Dehydro-TXB2 serves as a biomarker for research related to asthma, atopic rhinitis, nephropathy, and coronary artery disease.

LP-003 is an anti-IgE antibody that binds free human IgE with a K_d of 2.08 pM. LP-003 blocks the interaction of IgE with FcεRI and CD23, thereby preventing IgE-mediated signaling. LP-003 binds FcRn at acidic pH, reducing clearance and prolonging exposure. LP-003 inhibits IgE-mediated reporter gene expression. LP-003 can be used for research on seasonal allergic rhinitis.

Muscarinic M3/Histamine H1 receptor antagonist-1 is a selective muscarinic M3 receptor antagonist and histamine H1 receptor blocker. Muscarinic M3/Histamine H1 receptor antagonist-1 blocks M1, M2, and M4 muscarinic receptor signaling. Muscarinic M3/Histamine H1 receptor antagonist-1 inhibits nasal IL-33 and TSLP, but does not significantly reduce IL-4 or IL-13. Muscarinic M3/Histamine H1 receptor antagonist-1 reduces Capsaicin (HY-10448)-induced sneezing and nose rubbing. Muscarinic M3/Histamine H1 receptor antagonist-1 can be used in research on non-allergic rhinitis and allergic rhinitis.

Bradykinin (1-5) TFA is a metabolite of Bradykinin (HY-P0206) and a PAR inhibitor that inhibits thrombin-induced platelet aggregation by preventing protease-activated receptor (Protease Activated Receptor) cleavage and inhibiting Thrombin (MW 37kDa) (HY-114164). Bradykinin (1-5) TFA is used in research on thrombosis, carrageenan-induced pleurisy, nasal allergy, and hereditary angioedema.

11-Dehydro-thromboxane B2-¹³C₅ is the ¹³C-labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a stable terminal metabolite of thromboxane A2 and an agonist of the CRTH2 receptor. 11-Dehydro-TXB2 activates human eosinophils, basophils, and CRTH2-transfected BaF/3 cells through a pertussis toxin-insensitive G protein-PLC pathway, inducing intracellular calcium mobilization, morphological changes, and chemotaxis, but does not affect platelet aggregation. 11-Dehydro-thromboxane B2 is involved in thrombosis and promotes eosinophil recruitment to the lungs in allergic inflammation, and its urinary levels are used to assess the inhibitory effect of Aspirin (HY-14654) on thromboxane production. 11-Dehydro-TXB2 serves as a biomarker for research related to asthma, atopic rhinitis, nephropathy, and coronary artery disease.

Bakkenolide Iva is a bakkenolide-type sesquiterpene. Bakkenolide Iva is isolated from the rhizomes of Petasites tricholobus. Bakkenolide Iva inhibits lipid peroxidation in rat brain homogenates and scavenges DPPH free radicals. Bakkenolide Iva protects cortical neurons against oxygen-glucose deprivation-induced injury and oxidative stress-induced neuronal injury. Bakkenolide Iva can be used in research on paralysis and allergic rhinitis.

VAK-694 is a fully humanized anti-IL-4 monoclonal antibody. VAK-694 can be used for the research of seasonal allergic rhinitis.